| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8746083 | Journal of Global Antimicrobial Resistance | 2018 | 27 Pages |
Abstract
Rezafungin is a novel echinocandin currently in phase 2 studies, differentiated by a long half-life that allows once-weekly dosing and a safety profile that allows higher doses. Several potential areas of use for rezafungin were identified.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Amelia K. Sofjan, Ardath Mitchell, Dhara N. Shah, Tam Nguyen, Mui Sim, Ashley Trojcak, Nicholas D. Beyda, Kevin W. Garey,